ArticleJournal of the National Cancer Institute2026
Recent trends in Early-Onset cancer incidence rates.
Article in Journal of the National Cancer Institute, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
The increasing incidence of early-onset cancers is a growing concern. Using newly released Surveillance Epidemiology and End Results (SEER) data incorporating 2023 incidence rates, we evaluated emerging trends by comparing 5-year average annual percent changes (AAPC) in incidence rates for 2018-2022 and 2019-2023 across the 22 most common cancer types in individuals under 50 years of age. The AAPC changed significantly for liver and intrahepatic bile duct cancer from 2.6% (non-significant) in 2018-2022 to 3.7% (increasing) in 2019-2023. For non-Hodgkin lymphoma and lung and bronchus cancer, AAPCs changed from -0.5% to 1.1% and from -2.0% to 0.3%, respectively (decreasing to non-significant). A continuous increase in incidence rates was observed for cancers including but not limited to colorectal cancer (excluding appendix) and ovarian cancer. These findings underscore the need for robust cancer registry data to support surveillance research and inform prevention and control efforts in younger populations.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.